Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
07 2023
Historique:
revised: 20 04 2023
received: 30 12 2022
accepted: 09 05 2023
medline: 9 8 2023
pubmed: 21 5 2023
entrez: 21 5 2023
Statut: ppublish

Résumé

To assess the prevalence, clinical characteristics, and outcomes of patients with heart failure (HF) with or without moderate to severe aortic valve disease (AVD) (aortic stenosis [AS], aortic regurgitation [AR], mixed AVD [MAVD]). Data from the prospective ESC HFA EORP HF Long-Term Registry including both chronic and acute HF were analysed. Of 15 216 patients with HF (62.5% with reduced ejection fraction, HFrEF; 14.0% with mildly reduced ejection fraction, HFmrEF; 23.5% with preserved ejection fraction, HFpEF), 706 patients (4.6%) had AR, 648 (4.3%) AS and 234 (1.5%) MAVD. The prevalence of AS, AR and MAVD was 6%, 8%, and 3% in HFpEF, 6%, 3%, and 2% in HFmrEF and 4%, 3%, and 1% in HFrEF. The strongest associations were observed for age and HFpEF with AS, and for left ventricular end-diastolic diameter with AR. AS (adjusted hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.23-1.67), and MAVD (adjusted HR 1.37, 95% CI 1.07-1.74) but not AR (adjusted HR 1.13, 95% CI 0.96-1.33) were independently associated with the 12-month composite outcome of cardiovascular death and HF hospitalization. The associations between AS and the composite outcome were observed regardless of ejection fraction category. In the ESC HFA EORP HF Long-Term Registry, one in 10 patients with HF had AVD, with AS and MAVD being especially common in HFpEF and AR being similarly distributed across all ejection fraction categories. AS and MAVD, but not AR, were independently associated with increased risk of in-hospital mortality and 12-month composite outcome, regardless of ejection fraction category.

Identifiants

pubmed: 37210639
doi: 10.1002/ejhf.2908
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1049-1060

Informations de copyright

© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M, et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021;18:853-864. https://doi.org/10.1038/s41569-021-00570-z
Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19:100-116. https://doi.org/10.1038/s41569-021-00605-5
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574-1585. https://doi.org/10.1002/ejhf.813
Kaplon-Cieslicka A, Benson L, Chioncel O, Crespo-Leiro MG, AJS C, Anker SD, et al.; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022;24:335-350. https://doi.org/10.1002/ejhf.2408
Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624-1634. https://doi.org/10.1002/ejhf.945
Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: A nationwide cohort study. Circ Heart Fail. 2017;10:e003875. https://doi.org/10.1161/CIRCHEARTFAILURE.117.003875
Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Ponikowski P, et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail. 2017;19:1569-1573. https://doi.org/10.1002/ejhf.1058
Abdurashidova T, Monney P, Tzimas G, Soborun N, Regamey J, Daux A, et al. Non-severe aortic regurgitation increases short-term mortality in acute heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7:3901-3909. https://doi.org/10.1002/ehf2.12983
Verbrugge FH, Reddy YNV, Eleid MF, Lin G, Burkhoff D, Borlaug BA. Mild aortic valve disease and the diastolic pressure-volume relationship in heart failure with preserved ejection fraction. Open Heart. 2021;8:e001701. https://doi.org/10.1136/openhrt-2021-001701
Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39:3439-3450. https://doi.org/10.1093/eurheartj/ehy531
Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015;17:925-935. https://doi.org/10.1002/ejhf.327
Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74:2858-2873. https://doi.org/10.1016/j.jacc.2019.09.063
Chieffo A, Van Mieghem NM, Tchetche D, Dumonteil N, Giustino G, Van der Boon RM, et al. Impact of mixed aortic valve stenosis on VARC-2 outcomes and postprocedural aortic regurgitation in patients undergoing transcatheter aortic valve implantation: Results from the international multicentric study PRAGMATIC (Pooled Rotterdam-Milan-Toulouse in Collaboration). Catheter Cardiovasc Interv. 2015;86:875-885. https://doi.org/10.1002/ccd.25975
Hahn RT, Pibarot P, Stewart WJ, Weissman NJ, Gopalakrishnan D, Keane MG, et al. Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: A longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (placement of aortic transcatheter valves). J Am Coll Cardiol. 2013;61:2514-2521. https://doi.org/10.1016/j.jacc.2013.02.087
Van Belle E, Juthier F, Susen S, Vincentelli A, Iung B, Dallongeville J, et al. Postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures: Analysis of predictors and impact on long-term mortality: Insights from the FRANCE2 Registry. Circulation. 2014;129:1415-1427. https://doi.org/10.1161/CIRCULATIONAHA.113.002677
Marciniak A, Glover K, Sharma R. Cohort profile: Prevalence of valvular heart disease in community patients with suspected heart failure in UK. BMJ Open. 2017;7:e012240. https://doi.org/10.1136/bmjopen-2016-012240
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006;368:1005-1011. https://doi.org/10.1016/S0140-6736(06)69208-8
Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613-625. https://doi.org/10.1002/ejhf.566
White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30:377-399. https://doi.org/10.1002/sim.4067
Shahim B, Cohen DJ. Transporting results of TAVR trials to the real world: A long and winding road. JACC Cardiovasc Interv. 2021;14:2124-2126. https://doi.org/10.1016/j.jcin.2021.08.029
Gomberg-Maitland M, Shah SJ, Guazzi M. Inflammation in heart failure with preserved ejection fraction: Time to put out the fire. JACC Heart Fail. 2016;4:325-328. https://doi.org/10.1016/j.jchf.2015.11.013
Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. https://doi.org/10.1016/j.jacc.2013.02.092
Carabello BA. Aortic regurgitation. A lesion with similarities to both aortic stenosis and mitral regurgitation. Circulation. 1990;82:1051-1053. https://doi.org/10.1161/01.cir.82.3.1051
Popescu AC, Antonini-Canterin F, Enache R, Nicolosi GL, Piazza R, Faggiano P, et al. Impact of associated significant aortic regurgitation on left ventricular remodeling and hemodynamic impairment in severe aortic valve stenosis. Cardiology. 2013;124:174-181. https://doi.org/10.1159/000346623
Chahine J, Kadri AN, Gajulapalli RD, Krishnaswamy A, Mick S, Perez O, et al. Outcomes of transcatheter aortic valve replacement in mixed aortic valve disease. JACC Cardiovasc Interv. 2019;12:2299-2306. https://doi.org/10.1016/j.jcin.2019.06.020
Panagides V, Alperi A, Mesnier J, Philippon F, Bernier M, Rodes-Cabau J. Heart failure following transcatheter aortic valve replacement. Expert Rev Cardiovasc Ther. 2021;19:695-709. https://doi.org/10.1080/14779072.2021.1949987
Khanji MY, Ricci F, Galusko V, Sekar B, Chahal CAA, Ceriello L, et al. Management of aortic stenosis: A systematic review of clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes. 2021;7:340-353. https://doi.org/10.1093/ehjqcco/qcab016
Markham R, Ghodsian M, Sharma R. TAVR in patients with pure aortic regurgitation: Ready to use? Curr Cardiol Rep. 2020;22:98. https://doi.org/10.1007/s11886-020-01338-6
Mondal S, Ashish K, Bandyopadhyay D, Ghosh RK. Role of TAVR in pure native valvular aortic regurgitation: A new paradigm. Int J Cardiol. 2018;265:82. https://doi.org/10.1016/j.ijcard.2018.02.056
Poschner T, Werner P, Kocher A, Laufer G, Musumeci F, Andreas M, et al. The JenaValve pericardial transcatheter aortic valve replacement system to treat aortic valve disease. Future Cardiol. 2022;18:101-113. https://doi.org/10.2217/fca-2021-0065
Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209-2216. https://doi.org/10.1001/jama.296.18.2209

Auteurs

Bahira Shahim (B)

Unit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Angiza Shahim (A)

Unit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Marianna Adamo (M)

Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Ovidiu Chioncel (O)

Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', University of Medicine Carol Davila, Bucharest, Romania.

Lina Benson (L)

Unit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Maria G Crespo-Leiro (MG)

Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Complexo Hospitalario Universitario A Coruna, CHUAC, INIBIC, UDC, CIBERCV, La Coruna, Spain.

Stefan D Anker (SD)

Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.

Andrew J S Coats (AJS)

Scientific Director, Heart Research Institute, Sydney, NSW, Australia.

Gerasimos Filippatos (G)

Heart Failure Unit, Department of Cardiology, University Hospital Attikon, National and Kapodistrian Univeristy of Athens, Athens, Greece.

Mitja Lainscak (M)

Division of Cardiology, Murska Sobota, Murska Sobota and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Theresa McDonagh (T)

King's College Hospital, London, UK.

Alexandre Mebazaa (A)

Department of Anesthesia-Burn-Critical Care, UMR 942 Inserm - MASCOT, APHP Saint Louis Lariboisière University Hospitals, University of Paris, Paris, France.

Massimo F Piepoli (MF)

IRCCS Policlinico San Donato, San Donato Milanese, Italy.

Giuseppe M C Rosano (GMC)

IRCCS San Raffaele Pisana, Rome, Italy.

Frank Ruschitzka (F)

University Hospital, Clinic of Cardiology, Zürich, Switzerland.

Gianluigi Savarese (G)

Unit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Petar Seferovic (P)

University of Belgrade Faculty of Medicine, Belgrade, Serbia.

Maurizio Volterrani (M)

IRCCS San Raffaele, Rome, Italy.

Marisa Crespo Leiro (M)

Complexo Hospitalario Universitario A Coruna (Juan Canalejo), La Coruna, Spain.

Javier Segovia Cubero (J)

Hospital Universitario Puerta de Hierro, Majadahonda, Spain.

Offer Amir (O)

Lady Davis Carmel Medical Center, Haifa, Israel.

Benjamin Palic (B)

University Clinical Hospital, Mostar, Bosnia and Herzegovina.

Aldo P Maggioni (AP)

ANMCO Research Center, Heart Care Foundation, Florence, Italy.

Marco Metra (M)

Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Lars H Lund (LH)

Unit of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH